---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Phase of product development"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Phase of product development. Topics: Regulatory status: Submission planned; NDA planned for the fourth quarter of 2026; Investigational status; NDA submission planned for the second half of 2026, January 2026, superseded in May 2026; First statement of an NDA submission in the fourth quarter of 2026, May 2026; 19 further topics. 23 evidence topics quoted from 21 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Submission planned; NDA planned for the fourth quarter of 2026

> “Alumis remains on track to submit its New Drug Application to the FDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.”
> “Our fourth-quarter 2026 NDA submission remains on track.”
> “NDA submission (4Q 2026).”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

> “We plan to submit an NDA for envu in PsO to the U.S. Food and Drug Administration (“FDA”) by the end of 2026.”
> “prepare to submit an NDA for envu in PsO by the end of 2026, including as we conduct activities that are required to complete our planned NDA submission;”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Investigational status

> “Envudeucitinib is an investigational drug, not reviewed or approved by any regulatory agency”

Source: [Alumis envudeucitinib for psoriasis page](https://www.alumis.com/pipeline/envudeucitinib-for-psoriasis/)

<a id="topic-2.1.1-4"></a>

### NDA submission planned for the second half of 2026, January 2026, superseded in May 2026

> “Alumis plans to present additional results from ONWARD1 and ONWARD2 at an upcoming medical meeting and to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration in the second half of this year.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

> “Plan to submit NDA for envudeucitinib in PsO in 2H 2026”
> “NDA submission (2H2026)”

Source: [Alumis press release, year end 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)

> “We plan to submit an NDA for envu in PsO to the FDA in the second half of 2026.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

> “Alumis is continuing to evaluate the long-term efficacy and safety of envudeucitinib in the ONWARD3 long-term extension trial and plans to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of this year.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-2.1.1-5"></a>

### First statement of an NDA submission in the fourth quarter of 2026, May 2026

> “Data continue to underscore envudeucitinib’s potential as a leading oral therapy for PsO; plans to submit NDA in 4Q 2026 remain on track”
> “We remain on track for our NDA submission in the fourth quarter of this year, as well as the potentially pivotal LUMUS Phase 2b topline readout in SLE in the third quarter.”

Source: [Alumis press release, first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000009/alms-20260514xex99d1.htm)

<a id="topic-2.1.1-6"></a>

### Development history: first phase 2 and phase 3 dosing milestones

> “In the year ended December 31, 2022, we incurred and made a $37.0 million milestone payment for the first administration of envu to a patient enrolled in a Phase 2 clinical trial of envu, which was recorded in research and development expenses in the consolidated statement of operations and comprehensive loss.”
> “In July 2024, we met a milestone in connection with the first administration of envu to a patient enrolled in a Phase 3 clinical trial of envu and made a $23.0 million milestone payment in August 2024, which was recorded in research and development expenses in the consolidated statement of operations and comprehensive loss for the year ended December 31, 2024.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.1-7"></a>

### Development history: ONWARD enrollment in March 2025 and completion of enrollment in August 2025

> “ONWARD Phase 3 development program in plaque psoriasis ongoing, with over 600 patients enrolled to date”

Source: [Blauvelt et al. (2025a)](https://www.alumis.com/file.cfm/18/docs/aad2025_blauvelt_et_al_esk-001_52w_ole_vf.pdf)

> “Completed enrollment in Phase 3 ONWARD clinical trials for envudeucitinib in moderate-to-severe plaque psoriasis; topline readout expected in early Q1 2026”

Source: [Alumis press release, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)

<a id="topic-2.1.1-8"></a>

### Development history: ONWARD1 and ONWARD2 topline results, January 2026

> “SOUTH SAN FRANCISCO, Calif., Jan. 6, 2026 -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced positive topline results from its Phase 3 ONWARD1 and ONWARD2 clinical trials of envudeucitinib, a next-generation highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis.”

Source: [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm)

> “We completed the pivotal Phase 3 ONWARD1 and ONWARD2 clinical trials of envu in patients with PsO, and reported positive topline results in the first quarter of 2026.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.1-9"></a>

### Development history: AAD 2026 late-breaking presentation of ONWARD1 and ONWARD2, March 2026

> “SOUTH SAN FRANCISCO, Calif., March 28, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new data from its Phase 3 ONWARD1 and ONWARD2 clinical trials evaluating envudeucitinib, a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor for moderate-to-severe plaque psoriasis.”
> “The data were presented in a late-breaking oral session at the 2026 AAD Annual Meeting.”

Source: [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm)

<a id="topic-2.1.1-10"></a>

### Development history: ONWARD3 topline results, August 2026

> “SOUTH SAN FRANCISCO, Calif., August 10, 2026 – Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced topline results from the ongoing ONWARD3 long-term extension (LTE) study.”

Source: [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm)

> “We reported data from the ongoing ONWARD3 LTE trial in the second half of 2026.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.1-11"></a>

### Development history: Fall Clinical Dermatology Conference presentation of ONWARD1, ONWARD2, and ONWARD3, October 2026

> “SOUTH SAN FRANCISCO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new envudeucitinib data from the ONWARD Phase 3 clinical program—ONWARD1, ONWARD2, and the long-term extension ONWARD3.”
> “The results, presented at the 26th Annual Fall Clinical Dermatology Conference, reinforce the potential of envudeucitinib to become a leading oral therapy for patients with moderate-to-severe plaque psoriasis.”

Source: [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib)

<a id="topic-2.1.1-12"></a>

### ONWARD1 and ONWARD2 topline data expected in the first half of 2026, November 2024, superseded in March 2025

> “ESK-001: Psoriasis Phase 3 topline data (1H 2026)”

Source: [Alumis press release, third quarter 2024 results (2024)](https://www.sec.gov/Archives/edgar/data/1847367/000110465924117704/tm2428191d1_ex99-1.htm)

<a id="topic-2.1.1-13"></a>

### ONWARD1 and ONWARD2 topline data expected in the first quarter of 2026, March 2025, superseded in May 2025

> “We continue to progress and enroll patients with moderate-to-severe psoriasis in the pivotal Phase 3 ONWARD studies and expect to report topline data in the first quarter of 2026.”

Source: [Alumis press release, AAD 2025 OLE data (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925021990/tm258686d1_ex99-1.htm)

> “Phase 3 ONWARD program data readout now expected 1Q 2026”

Source: [Alumis press release, year end 2024 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000010/tmb-20250319xex99d1.htm)

<a id="topic-2.1.1-14"></a>

### ONWARD1 and ONWARD2 topline data expected early in the first quarter of 2026, May 2025, superseded in January 2026

> “This includes advancement of the ongoing clinical trials for ESK-001 moving steadily toward pivotal topline Phase 3 data for our next-generation TYK2 inhibitor ESK-001 in moderate-to-severe plaque psoriasis now expected early in the first quarter of 2026 and data from ESK-001’s Phase 2b clinical trial in systemic lupus erythematosus expected in 2026.”

Source: [Alumis press release, first quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000026/alms-20250514xex99d1.htm)

> “Topline data from ONWARD1 and ONWARD2 are expected early in the first quarter of 2026.”

Source: [Alumis press release, second quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000039/alms-20250813xex99d1.htm)

> “Envu: topline data from ONWARD1 and ONWARD2 in moderate-to-severe plaque psoriasis are expected early in the first quarter of 2026.”

Source: [Alumis press release, third quarter 2025 results (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000184736725000048/alms-20251113xex99d1.htm)

<a id="topic-2.1.1-15"></a>

### Phase 2 two-year safety data planned for the fourth quarter of 2026

> “Long-term data: Phase 2, two-year safety data (4Q 2026).”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

<a id="topic-2.1.1-16"></a>

### Phase 2 two-year safety data planned for the second half of 2026, March 2026, superseded in November 2026

> “Long-term data - ONWARD3 topline data and Phase 2, two-year safety data (2H 2026)”

Source: [Alumis press release, year end 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)

> “Long-term data: Phase 2, two-year safety data (2H 2026)”

Source: [Alumis press release, second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000016/alms-20260813xex99d1.htm)

<a id="topic-2.1.1-17"></a>

### Going concern disclosure and cash runway statement, November 2026

> “The Company believes that, based on its current operating plan, its existing cash, cash equivalents and marketable securities of $431.3 million as of September 30, 2026, will not be sufficient to meet its operating and capital requirements for at least 12 months from the date of issuance of these unaudited condensed consolidated financial statements and there is substantial doubt about the Company’s ability to continue as a going concern.”
> “The Company will need to raise significant additional capital to fund ongoing research and development activities, support potential commercialization including market and launch preparation activities and maintain future operations.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

> “Based on the Company’s current operating plan, Alumis continues to anticipate that its existing cash, cash equivalents and marketable securities as of September 30, 2026 are sufficient to fund operating expenses and capital expenditure requirements into the fourth quarter of 2027.”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

<a id="topic-2.1.1-18"></a>

### Liquidity sufficient for at least 12 months, August 2026, superseded in November 2026

> “Based on our current operating plan, our existing cash, cash equivalents and marketable securities of $502.3 million as of June 30, 2026, will be sufficient to meet our operating and capital requirements for at least 12 months from the date of issuance of the unaudited condensed consolidated financial statements included in Part I Item 1 of this Quarterly Report on Form 10-Q.”

Source: [Alumis Form 10-Q, second quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000018/alms-20260630x10q.htm)

<a id="topic-2.1.1-19"></a>

### Financing: January 2026 public offering

> “Completed an upsized public offering raising $345.1 million in gross proceeds in Jan 2026”
> “Completed closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters’ option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share”

Source: [Alumis press release, year end 2025 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)

<a id="topic-2.1.1-20"></a>

### Financing: at-the-market sales agreement of March 2026

> “On March 18, 2026, we entered into the Sales Agreement with Cantor as sales agent, pursuant to which we may offer and sell, from time to time through Cantor, at our option, the ATM Shares.”
> “The ATM Shares include shares of our common stock having an aggregate offering price of up to $300.0 million.”
> “As of the date of issuance of these financial statements, no ATM Shares have been sold under the Sales Agreement.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

<a id="topic-2.1.1-21"></a>

### Patent protection: composition of matter, crystalline and salt forms, and methods of treatment

> “In regard to envu and A-005, we own one patent family with claims directed to composition of matter and methods of use that includes five issued U.S. patents, one pending U.S. patent application, over fifteen granted foreign patents in Europe (each validated in over 35 countries), and certain other countries, and over 10 foreign patent applications pending in various jurisdictions, such as Europe and Japan.”
> “Not accounting for any patent term adjustment or extensions or terminal disclaimers, and assuming that all applicable annuity and/or maintenance fees are paid timely, the issued patents, and, if granted, the pending patent applications in this family, are expected to expire in 2039.”
> “We also own three patent families with claims directed to crystalline and salt forms of envu, which includes three pending U.S. applications, and over 30 foreign patent applications pending in various jurisdictions such as Europe and Japan.”
> “Not accounting for any patent term adjustment or extension and assuming that all applicable annuity and/or maintenance fees are paid timely, the patent applications, if issued, and any patent applications claiming the benefit of these PCT applications, if issued, will be expected to expire in 2043.”
> “We own one patent family with claims directed to methods of treating a TYK2-mediated disease using envu, that includes a pending U.S. application and over 10 foreign applications pending in various jurisdictions such as Europe and Japan.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.1-22"></a>

### Cumulative clinical exposure: more than 2,000 participants

> “Envu has been administered to more than 2,000 participants and in some cases administered for up to three years.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.1-23"></a>

### Japan dermatology rights licensed to Kaken Pharmaceutical, March 2025

> “On March 25, 2025 (the “Effective Date”), the Company entered into the Kaken Collaboration Agreement.”
> “Under the terms of the Kaken Collaboration Agreement, the Company granted to Kaken an exclusive right to develop, manufacture and commercialize envu for dermatology indications in Japan, with options to expand the license, subject to opt-in payments and certain cost-sharing obligations on the part of Kaken, to include rheumatological and gastrointestinal diseases.”

Source: [Alumis Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000024/alms-20260930x10q.htm)

> “Kaken will be responsible for the clinical development, regulatory approvals and commercialization of ESK-001 in Japan, and Alumis will retain rights to ESK-001 in all other geographies.”

Source: [Alumis and Kaken press release, collaboration and licensing agreement (2025)](https://www.sec.gov/Archives/edgar/data/1847367/000110465925027444/tm2510181d1_ex99-1.htm)

<a id="topic-2.1.1-24"></a>

### LUMUS phase 2b trial in systemic lupus erythematosus: topline results, September 2026

> “SOUTH SAN FRANCISCO, Calif., September 1, 2026 – Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that its Phase 2b LUMUS trial of envudeucitinib for the treatment of moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary and secondary endpoints in the overall trial population.”
> “In LUMUS, IFNGS-high patients were unexpectedly under-represented, reducing response rates in the overall trial population.”
> “We are actively evaluating opportunities to maximize the value of our oral TYK2 portfolio and remain on track to file an NDA for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of this year.”

Source: [Alumis press release, LUMUS topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-1.htm)

> “Alumis plans to conduct end-of-Phase 2 regulatory interactions and evaluate development options.”

Source: [Alumis press release, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000022/alms-ex99d1.htm)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
